Recent Updates
Recently added Catalysts

Uridine 5'-Triphosphate for

Phase 3

Lung Cancer | Small molecule | Oncology |Merck & Company, Inc.|Last Updated: Sep 4, 2015

Target and mechanism

ModalitySmall molecule

Also known as Uridine 5'-Triphosphate (UTP) Solution for Inhalation

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment700

FDA Designations

No designations recorded

Clinical trial landscape

Uridine 5'-Triphosphate for · 1 trial · 1 indication

Phase 3 1
NCT00210080A Study to Diagnose Lung Cancer by Sputum Cytology (01-312)Lung Cancer
COMPLETED700 Analytics
PHASE3COMPLETED
A Study to Diagnose Lung Cancer by Sputum Cytology (01-312)
Lung Cancer
NCT00210080700
Unlock trial analytics

Study Endpoints

Primary Endpoints

Proportion of lung cancers (malignancies) diagnosed by sputum cytology

Secondary Endpoints

Proportion of centrally and peripherally located lung cancers diagnosed by sputum cytology;
Proportion of small and large lung cancers diagnosed by sputum cytology;
Proportion of lung cancers of various cell types, stages and resectability diagnosed by sputum cytology;
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Interventions

NameTypeDescription
Uridine 5'-Triphosphate (UTP) Solution for InhalationDRUG -
Unlock Study Design Details

Eligibility Criteria

Healthy VolunteersNo

Inclusion Criteria: * be suspected of having primary lung cancer based upon chest radiograph(s), CT scan(s), or PET scan(s) and with symptom, risk profile, or history suggestive of malignancy * have FEV1 greater than or equal to 40% predicted normal for age and height Exclusion Criteria: * have o...

Unlock Eligibility Criteria

Competitive Landscape -Lung Cancer 280 trials

Top 20 of 76 competitors

CompanyTickerTrialsLead PhaseDrugs
Merck & Co., Inc.MRK10PHASE3Pembrolizumab, Olaparib, Etoposide/m^2
Gilead Sciences, Inc.GILD5PHASE3Sacituzumab Govitecan, Topotecan, Amrubicin, Lurbinectedin
Amgen Inc.AMGN14PHASE3Tarlatamab, Durvalumab, Carboplatin, Etoposide
AstraZeneca PLCAZN31PHASE3Durvalumab
BioNTech SE Sponsored ADRBNTX6PHASE3PM8002, Paclitaxel, Topotecan
Pfizer Inc.PFE13PHASE3PF-08634404, Pembrolizumab, Chemotherapy Regimen 1
AbbVie, Inc.ABBV4PHASE3ABBV-706, Topotecan, Lurbinectedin, Amrubicin
Bristol-Myers Squibb CompanyBMY14PHASE3MRTX849, Docetaxel
ArriVent BioPharma, Inc.AVBP6PHASE3furmonertinib, daily, platinum-based chemotherapy
Eli Lilly and CompanyLLY3PHASE3Ramucirumab, Erlotinib, Gefitinib, Osimertinib
Jazz Pharmaceuticals Public Limited CompanyJAZZ3PHASE3Atezolizumab, Lurbinectedin, Carboplatin, Etoposide
Revolution Medicines, Inc.RVMD2PHASE3daraxonrasib, docetaxel
Summit Therapeutics IncSMMT1PHASE3AK112
Takeda Pharmaceutical Co. Ltd. Sponsored ADRTAK1PHASE3TAK-788, Pemetrexed, Cisplatin, Carboplatin
Immutep Ltd Sponsored ADRIMMP2PHASE3eftilagimod alfa, carboplatin plus paclitaxel, cisplatin or carboplatin, pemetrexed, pembrolizumab
Regeneron Pharmaceuticals, Inc.REGN5PHASE2BNT116, Cemiplimab
GSK plc Sponsored ADRGSK1PHASE3Ris-Rez, Topotecan
Zai Lab Ltd. Sponsored ADRZLAB2PHASE3ZL-1310
NovoCure Ltd.NVCR1PHASE3Pembrolizumab, Platinum based chemotherapy
ImmunityBio IncIBRX2PHASE3N-803, Tislelizumab, Docetaxel, Prior failed checkpoint inhibitor
Unlock Competitive Intelligence